Managing conflicts of interest in national pharmaceutical systems

4 October 2022 14:00 – 15:25 CET
Proportionality. Transparency. Accountability. Fairness.
These principles are all vital in developing policies and taking action to guard against conflicts of interest. 
WHO—in collaboration with the United States Agency for International Development Medicines, Technologies, and Pharmaceutical Services Program— is holding an information session to present its new how-to guide on how to manage conflicts of interest for public pharmaceutical sector committees in low- and middle-income countries. 
The public pharmaceutical sector is composed of institutions that make decisions on medicines policy and regulatory issues to ensure access to safe, quality-assured, and efficacious medicines.
The session will cover ten key steps for improving conflict of interest policy, prevention, and management in public pharmaceutical decision-making committees. 
The event will also offer a deep dive on addressing conflicts of interest in the South East Asia region, with presentations from Malaysia's Pharmaceutical Regulatory Agency and Uganda's National Drug Authority to share experiences and good practices from in-country.